Venture capital investment in the biopharma sector slowed significantly in 2025, with Massachusetts—one of the industry’s main centers—seeing VC funding fall to $6.85 billion, its lowest since 2019. In comparison, the state received $7.89 billion in venture capital in 2024, according to MassBio’s annual report.
MassBio attributed the downturn during the first half of 2025 to “reluctant private investors, a closed IPO window, cautious pharma, and layoffs.” However, conditions improved later in the year. Approximately 60% of all VC funding for Massachusetts companies was announced in the second half of 2025.
“Decreased interest rates and increasing clarity on pricing and tariffs enabled a stronger second half period,” a MassBio representative said in an email to BioSpace. The group also noted in its news release that “a stronger second half of the year in VC funding and M&A [mergers & acquisitions] activity is a trend to watch for the new year.”
Other analysts echoed this optimism. Leerink Partners stated it was “generally sanguine” about biopharma’s fundraising prospects as momentum returns and generalist investors show renewed interest. According to Leerink’s December 17 report, policy and regulatory issues that dominated early 2025 have been replaced by positive clinical developments and more stable guidance: “have mostly been replaced by enthusiasm for rebased guidance, positive clinical news, and several sectors navigating much (but not all) of the uncertainty in Washington,” Leerink said.
The MassBio report also indicated that Massachusetts-based companies are well-positioned moving into 2026. The region saw its drug development pipeline expand by 14% over the previous year—more than double the national average increase of 6.8%. Much of this growth came from an uptick in preclinical research focused on cancer therapies and treatments for central nervous system disorders.
While Massachusetts experienced notable growth, China’s drug development pipeline grew even faster at over 37%, driven by government investment and streamlined regulations. This rapid expansion has drawn attention from U.S. policymakers as competition intensifies between American firms and their Chinese counterparts.
